The impact of brivaracetam on cognitive processes and anxiety in various experimental models

Pharmacol Rep. 2024 Feb;76(1):86-97. doi: 10.1007/s43440-023-00564-3. Epub 2024 Jan 5.

Abstract

Background: Memory deficits and anxiety symptoms are undesirable effects that occur in epilepsy patients. They may be associated with the pathophysiology of the disease but also with anticonvulsant therapy. Brivaracetam (BRV) is one of the newest antiseizure drugs. It acts as a ligand for synaptic vesicle glycoprotein 2A (SV2A), which may play a significant role in cognitive processes. Although BRV has a favorable safety profile, its central side effects remain unclear. Hence, this study aimed to evaluate the effect of BRV on various types of memory and anxiety in rats.

Methods: BRV was given to adult male Wistar rats (n = 80) via gastric tube as a single dose (6 mg/kg or 20 mg/kg) or chronically (6 mg/kg). The effect of the drug on spatial memory was evaluated in the Morris water maze (MWM), fear-learning by passive avoidance (PA), and recognition memory with novel object recognition (NOR). The elevated plus maze (EPM) was used to assess anxiety-like behaviors.

Results: The impact of BRV on memory is dose-dependent and mainly high doses may alter retrieval memory and fear-learning. Sub-chronic administration also impaired retrieval and spatial memory in animals. Moreover, chronic BRV may increase anxiety levels in rats but did not affect recognition memory.

Conclusions: BRV may cause transient memory deficits as well as anxiety disturbances. However, the results are varied and depend on the type of memory, used dose, and duration of administration.

Keywords: Anxiety; Brivaracetam; Cognitive processes; Memory; Rats.

MeSH terms

  • Adult
  • Animals
  • Anticonvulsants* / therapeutic use
  • Anxiety / drug therapy
  • Cognition
  • Humans
  • Male
  • Memory Disorders / chemically induced
  • Memory Disorders / drug therapy
  • Pyrrolidinones* / pharmacology
  • Rats
  • Rats, Wistar
  • Treatment Outcome

Substances

  • brivaracetam
  • Anticonvulsants
  • Pyrrolidinones